MARKET

ALEC

ALEC

Alector
NASDAQ
9.16
+0.19
+2.12%
After Hours: 8.98 -0.18 -1.97% 19:00 01/27 EST
OPEN
8.95
PREV CLOSE
8.97
HIGH
9.28
LOW
8.95
VOLUME
363.72K
TURNOVER
0
52 WEEK HIGH
17.68
52 WEEK LOW
6.85
MARKET CAP
757.55M
P/E (TTM)
-5.6062
1D
5D
1M
3M
1Y
5Y
Morgan Stanley Sticks to Its Hold Rating for Alector (ALEC)
TipRanks · 3d ago
Morgan Stanley Adjusts Price Target on Alector to $11 From 13, Maintains Equalweight Rating
Morgan Stanley Adjusts Price Target on Alector to $11 From 13, Maintains Equalweight Rating
MT Newswires · 4d ago
Mizuho Securities Remains a Buy on Alector (ALEC)
TipRanks · 01/18 09:15
Alector Presents Results From First-in-Human Phase 1 Study Of AL101 For The Treatment Of Neurodegenerative Diseases
Benzinga · 11/29/2022 16:06
Alector Says Phase 1 Study of AL101 for Neurodegenerative Disease Treatment Shows Elevated Progranulin Levels in Brain
Alector Says Phase 1 Study of AL101 for Neurodegenerative Disease Treatment Shows Elevated Progranulin Levels in Brain
MT Newswires · 11/29/2022 13:43
Citigroup Maintains Buy on Alector, Lowers Price Target to $17
Benzinga · 11/10/2022 12:53
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
Benzinga · 11/10/2022 10:12
--Citigroup Adjusts Price Target on Alector to $17 From $19, Maintains Buy Rating
--Citigroup Adjusts Price Target on Alector to $17 From $19, Maintains Buy Rating
MT Newswires · 11/10/2022 10:11
More
About ALEC
Alector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The Company is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. The Company has advanced four product candidates, AL001, AL002, AL003, and AL101, into clinical development. Its first product candidate, AL001, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients. Its AL002 targets triggering receptor expressed on myeloid cells 2 (TREM2) to increase the functionality of TREM2 signaling and enhance microglia cell activation.

Webull offers kinds of Alector Inc stock information, including NASDAQ:ALEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALEC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALEC stock methods without spending real money on the virtual paper trading platform.